[
    [
        {
            "time": "2018-01-02",
            "original_text": "A Closer Look at Biogen’s Gross Margin Trends",
            "features": {
                "keywords": [
                    "Biogen",
                    "gross margin",
                    "trends"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A Closer Look at Biogen’s Gross Margin Trends",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?",
            "features": {
                "keywords": [
                    "Franklin LibertyQ",
                    "ETF",
                    "FLQL",
                    "strong"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Stocks - Ciena Jumps in Premarket, Apple Gains, Tailored Brands Crashes",
            "features": {
                "keywords": [
                    "Ciena",
                    "Apple",
                    "Tailored Brands",
                    "premarket",
                    "jumps",
                    "gains",
                    "crashes"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "technology",
                    "retail"
                ],
                "causal_factor": "true",
                "causal_impact": "mixed",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "scores": {
                "News_content": "Stocks - Ciena Jumps in Premarket, Apple Gains, Tailored Brands Crashes",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug",
            "features": {
                "keywords": [
                    "Lilly",
                    "AC Immune",
                    "Alzheimer's",
                    "drug",
                    "deal"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "See what the IHS Markit Score report has to say about Eli Lilly and Co.",
            "features": {
                "keywords": [
                    "IHS Markit",
                    "score",
                    "Eli Lilly",
                    "report"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "See what the IHS Markit Score report has to say about Eli Lilly and Co.",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)",
            "features": {
                "keywords": [
                    "FDA",
                    "Fast Track",
                    "Baricitinib",
                    "SLE",
                    "development"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease",
            "features": {
                "keywords": [
                    "Boehringer Ingelheim",
                    "Lilly",
                    "Duke Clinical Research Institute",
                    "Type 2 Diabetes",
                    "Cardiovascular Disease",
                    "partnership"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "Eli Lilly: FDA Grants Fast Track Designation To Baricitinib Development Program",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "FDA",
                    "Fast Track",
                    "Baricitinib",
                    "development"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly: FDA Grants Fast Track Designation To Baricitinib Development Program",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]